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Background: There is an increased attention to stroke following SARS-CoV-2. The goal of this study was to
better depict the short-term risk of stroke and its associated factors among SARS-CoV-2 hospitalized patients.
Methods: This multicentre, multinational observational study includes hospitalized SARS-CoV-2 patients
from North and South America (United States, Canada, and Brazil), Europe (Greece, Italy, Finland, and Tur-
key), Asia (Lebanon, Iran, and India), and Oceania (New Zealand). The outcome was the risk of subsequent
stroke. Centres were included by non-probability sampling. The counts and clinical characteristics including
laboratory findings and imaging of the patients with and without a subsequent stroke were recorded accord-
ing to a predefined protocol. Quality, risk of bias, and heterogeneity assessments were conducted according
to ROBINS-E and Cochrane Q-test. The risk of subsequent stroke was estimated through meta-analyses with
random effect models. Bivariate logistic regression was used to determine the parameters with predictive
outcome value. The study was reported according to the STROBE, MOOSE, and EQUATOR guidelines.
Findings: We received data from 26,175 hospitalized SARS-CoV-2 patients from 99 tertiary centres in 65
regions of 11 countries until May 1st, 2020. A total of 17,799 patients were included in meta-analyses. Among
them, 156(0.9%) patients had a stroke—123(79%) ischaemic stroke, 27(17%) intracerebral/subarachnoid hem-
orrhage, and 6(4%) cerebral sinus thrombosis. Subsequent stroke risks calculated with meta-analyses, under
low to moderate heterogeneity, were 0.5% among all centres in all countries, and 0.7% among countries with
higher health expenditures. The need for mechanical ventilation (OR: 1.9, 95% CI:1.13.5, p = 0.03) and the
presence of ischaemic heart disease (OR: 2.5, 95% CI:1.44.7, p = 0.006) were predictive of stroke.
Interpretation: The results of this multi-national study on hospitalized patients with SARS-CoV-2 infection
indicated an overall stroke risk of 0.5%(pooled risk: 0.9%). The need for mechanical ventilation and the history
of ischaemic heart disease are the independent predictors of stroke among SARS-CoV-2 patients.
Funding: None.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license.
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The occurrence of multiple heterogeneous complications asso-
ciated with Coronavirus disease 2019, SARS-CoV-2 infection, a
global pandemic [1,2], has led to several scientific reports and
news headlines. Li et al. published one of the first studies describ-
ing the risk of stroke among SARS-CoV-2 hospitalized patients [3].
They observed a 5% risk of ischaemic stroke, 0.5% cerebral venous
sinus thrombosis, and 0.5% cerebral hemorrhage. However, the
study was a single-center report of a limited number of patients
(N: 221). Since then, there have been several other case reports
and series describing the risk of stroke among SARS-CoV-2
patients [46].
Several studies have described different mechanisms in which
SARS-CoV-2 can induce neurological disorders and stroke [7,8]. Many
of these mechanisms focus on Angiotensin-Converting Enzyme-2
(ACE-2), the binding site for SARS-CoV-2, and the imbalance of its
function as a trigger of a cascade of events resulting in vasoconstric-
tion, high blood pressure, or thrombus formation [9,10]. Other stud-
ies propose immune-mediated mechanisms and overexpression of
cytokines [11], hypercoagulability state, and thromboembolism as
potential stroke etiologies [1214].
However, the increased risk of stroke is not exclusive to SARS-
CoV-2 and it has been reported in association with other viral respira-
tory infections [1523]. A slight increase in the risk of stroke inci-
dence was reported following influenza infection [18,19], or other
b-coronaviruses such as Middle East respiratory syndrome coronavi-
rus (MERS-CoV) [2023], and severe acute respiratory syndrome
(SARS) [2023]. In addition, severe sepsis and critical condition may
impose an additional risk for coagulopathy or new-onset of atrial
fibrillation, which can increase the risk of stroke [2427]. Consider-
ing the burden of stroke and its association with worse prognosis,
compared with non-stroke, among hospitalized patients [28], wedesigned a multi-national observational study to better depict the
short-term risk of stroke and its associated factors among SARS-CoV-
2 hospitalized patients.
2. Methods
2.1. Study design
Supplemental Material Document 1 (page 6) includes the details
of the study design. The study was conducted and reported according
to the Strengthening the Reporting of Observational Studies in Epide-
miology (STROBE) [29], Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) [30], Preferred Reporting Items
for Meta-analysis Of Observational Studies in Epidemiology (MOOSE)
[31], and Enhancing the QUAlity and Transparency Of health
Research (EQUATOR) guidelines [32]. This multicentre, multinational
observational study was designed by the investigators at the Neuro-
science Institute of Geisinger Health System, Pennsylvania, the
United States. The study included patients from North America (Can-
ada and the United States), South America (Brazil), Europe (Greece,
Italy, Finland, and Turkey), Asia (Lebanon, Iran, and India), and Oce-
ania (New Zealand). Data were recruited up to May 1st, 2020; the
beginning date of the study period was defined as the earliest date
that each participating center admitted SARS-CoV-2 patients. Centres
were included by non-probability sampling; the core investigators
invited their collaborators from many countries through personal
phone calls, email communications, and announcements on social
media platforms for professionals. The investigators and collabora-
tors also contacted local societies, hospitals, and other related organi-
zations, sometimes using local languages, in many of the affected
countries as early as March 27, 2020.
For this study, stroke was defined as ischaemic stroke, intracere-
bral hemorrhage, subarachnoid hemorrhage, and cerebral venous
Research in context
Evidence before this study
The authors have searched Medline, Embase, Google Scholar,
MedRxiv, and all popular journals in the field of cerebrovascular
diseases, in addition to forward and backward citation tracking
of the related articles by April 25, 2020, and updated to the sub-
mission date, with no restriction on publication type or lan-
guage. SARS-CoV-2, SARS-CoV, MERS-CoV, COVID-19,
coronavirus, neurological manifestations, cerebrovascular dis-
eases, stroke, thrombosis, intracranial hemorrhage, intracere-
bral hemorrhage, and related Mesh Terms and Emtree
vocabulary were used with different Boolean operations. Our
study is not limited to a systematic review of previously
reported cases; therefore, we did not provide details of the
search strategy in this paper. Our team has reported the search
results of neurological complications of SARS-CoV-2 in a sepa-
rate review paper (currently in Press). The relevant evidence
before this study was reviewed in the introduction and discus-
sion section of the manuscript. Briefly, there are several case
reports of cerebrovascular disease among patients with SARS-
CoV-2. The results of a single-center, retrospective, observa-
tional analysis of consecutive SARS-CoV-2 patients admitted to
Union Hospital, Wuhan, China from 16 January 2020 to 29 Feb-
ruary 2020 indicates that out of 221 patients, 5% developed
acute ischemic stroke, and 0.5% (1 patient) developed intracere-
bral hemorrhage. However, the study had several limitations. It
was a single-center report and no data about the outcome was
available.
Added-value of this study
There are increasing concerns regarding the neurological and
specifically cerebrovascular complications of SARS-CoV-2.
Articles defining the higher risk of strokes among SARS-CoV-2
patients were published in the New York Times, CNN health,
the Washington Post, and several other news outlets as early as
April 1st. Understanding the risk and characteristics of cerebro-
vascular events is critically important given their burden and
prognosis. Therefore, the goal of this study was to investigate
the risk and associated factors of acute cerebrovascular diseases
(ischemic stroke, intracranial hemorrhage including subarach-
noid hemorrhage, and cerebral venous thrombosis) among
patients with SARS-CoV-2 in a large population.
Implications of all the available evidence
The result of the current study suggests that although there is
an increased risk of cerebrovascular events in patients infected
with SARS-CoV-2, the risk is comparable to other viral infec-
tions and critical conditions. The evidence also indicates that
dependency on a ventilator and the presence of ischemic heart
disease are predictive of cerebrovascular complications. There-
fore clinicians and nurses should be monitoring critically ill
patients for symptoms of acute stroke. More studies are needed
to describe the etiologies of cerebrovascular diseases among
this patient cohort and define effective prevention strategies.
S. Shahjouei et al. / EBioMedicine 59 (2020) 102939 3thrombosis [33]. Ischaemic or haemorrhagic stroke was defined as
the rapid onset of a neurological deficit when there was evidence of
an acute ischaemic or haemorrhagic lesion on Computed Tomogra-
phy (CT) or Magnetic Resonance Imaging (MRI) consistent with the
symptoms. Cerebral venous or sinus thrombosis was defined as a
hyperintense signal in the involved vein or sinus as evidenced by CT
scan or MRI corresponding to other imaging findings and patients’symptoms. Patients who did not have neuroimaging confirmation of
an acute stroke were not included in this study. We further subclassi-
fied the ischaemic stroke lesions based on the pattern of the lesion
on diffusion-weighted imaging (DWI) or CT to lacunar [34], embolic/
large vessel athero-thromboembolism [35,36], and other phenotypes
(borderzone or equivocal lesions). As part of our protocol, we
requested that our local investigator review all the images with the
local radiologist and reach a consensus if there was a disagreement.
TOAST (the Trial of Org 10,172 in Acute Stroke Treatment) [37] was
not assessed in this study since many of the patients had not com-
pleted their stroke workup (echocardiogram, long-term cardiac mon-
itoring, etc.) at the time of data acquisition.
2.2. Participants
We included consecutive hospitalized SARS-CoV-2 patients and
recorded patients who had a subsequent and confirmed stroke—
ischaemic stroke, intracerebral hemorrhage, subarachnoid hemor-
rhage, and cerebral venous thrombosis. The study cohort in all
centres was defined as the total population of patients who were hos-
pitalized with a confirmed diagnosis of SARS-CoV-2, with or without
a subsequent stroke. We also included patients who initially pre-
sented to the hospital with a stroke-related chief complaint and were
found to have an imaging-confirmed acute stroke, but also had posi-
tive screening results for SARS2-CoV-2. Many tertiary centres espe-
cially in hot spots had routine polymerase chain reaction (PCR) or
chest CT scan screening for all admitted patients or for patients who
had any symptoms of SARS-CoV-2 infection. In addition, we made
attempts to capture SARS-CoV-2 patients who had stroke-related
readmission by regular follow-ups. Patients with 24 h of hospitaliza-
tion were eligible for this study, regardless of their length of stay. The
post-discharge follow-up protocol for SARS-CoV-2 patients varied in
different countries and different centres. However, every center
reported uniform and non-selective follow-ups for the study popula-
tion. In addition, attempts were made to consider all centres provid-
ing neurological services in the captured areas to maximize the
chance of recording early post-discharge stroke. In case there was a
closed-loop referral system between the different tertiary centres for
patients with neurological complications, we considered the total
number of hospitalized SARS-CoV-2 patients (whether they had a
stroke or not) in the whole referral system to estimate the frequency
of stroke.
Tominimize the heterogeneity between different regions regarding
the population screening protocols, only patients who were hospital-
ized for more than 24 h were included in this study. The preferred
diagnostic criteria for SARS-CoV-2 was defined according to the World
Health Organization (WHO) interim guidance [38]. Due to the limited
availability of PCR testing or concerns about its low predictive value,
several centres used a combination of the history of exposure, symp-
tomatology, and chest CT with or without PCR methods for diagnosis
confirmation (Supplemental Table 1, page 9). The onset of SARS-CoV-2
was considered as either the symptoms onset or positive test, which-
ever was first. There were no age or gender exclusion criteria. Given
the high diagnostic error associated with a transient ischaemic attack
(TIA) [3941], patients who had transient stroke-like symptoms and
no acute lesion on CT or MRI were not included in this study.
Collaborators were asked to provide three sets of data: (1) number
and clinical details of patients with a stroke, (2) total number and
high-level summary (age and sex proportion, the severity of SARS-
CoV-2 infection, mechanical ventilation, prognosis, and vital status)
on the study population, and (3) clinical and laboratory findings of
the study population (or at least a randomly generated subset). Data
were collected by a predefined common core protocol and detailed
documents for stroke cases and study population. Each center had
the option of sending either patient- or summary-level data per their
internal board approval. We only accepted patient-level data for our
4 S. Shahjouei et al. / EBioMedicine 59 (2020) 102939stroke patients. The age, sex, comorbidities, and laboratory findings
were requested for the stroke patients and study population. For
stroke patients, we also obtained additional data including the onset
of stroke and SARS-CoV-2, chest CT scan findings, a need for mechani-
cal ventilation, details of neurological investigations, and localization
of the event, National Institute of Health Stroke Scale (NIHSS), and
acute management and outcomes.
2.3. Outcomes
The primary goal of this study was to estimate the risk of stroke
among hospitalized SARS-CoV-2 patients. Data from the centres that
were unable to provide information on hospitalized patients were
not used for the calculation of risk estimate. We also compared the
baseline characteristics, comorbidities, and laboratory findings
among stroke cases and a subset of the study population and investi-
gated the parameters with higher predictive value for stroke occur-
rence.
2.4. Statistical analysis
Descriptive statistics were used to summarize the data. Demo-
graphic data, comorbidities, and laboratory findings were reported as
medians (interquartile range [IQR]), mean (standard deviations [SD]),
and under stratified categories when possible. Categorical variables
were reported as absolute frequencies and percentages. The data
which were provided on a qualitative scale rather than quantitative
value (such as C-reactive protein-CRP) or equivalents of the
requested items (such as glomerular filtration rates instead of creati-
nine) were excluded from the analyses. The comparison between cat-
egorical variables was conducted with the Pearson chi-square test,
while the differences among continuous variables were assessed by
independent t-test. Bivariate logistic regression was used to deter-
mine the parameters with predictive outcome value. The model’s
goodness of fit was assessed by Hosmer and Lemeshow test. Odds
ratios (OR) and corresponding 95% confidence intervals (95% CIs)
were reported. All tests were performed using IBM SPSS Statistics
version 26 [42] and p<0.05 was considered statistically significant.
We used the Risk of Bias in Exposure Studies (ROBINS-E) tool [43]
to assess the quality of the data received from each center. We evalu-
ated the potential bias on time-varying confounding (cases: the time
window between the infection and stroke, potential of capturing
late-onset strokes; study population: follow-up and reporting consis-
tency); selection of study participants (cases: influence of outcomes
on inclusion, local investigators’ judgement on possibility of causal-
ity/coincidence for selective reporting of cases, automated data
extraction and natural language processing or manual chart review;
study population: SARS-CoV-2 hospitalization criteria); verification
of exposure/diagnosis (defining the confirmed SARS-CoV-2 based on
imaging, symptoms, and PCR); missing data (cases: data to confirmed
the diagnosis, stroke imaging pattern, and localization; study popula-
tion: high level summary data on hospitalized patients); measure-
ment of outcomes (awareness of the local investigators of all strokes
admitted in the center, consistent definition when referring to
stroke); and measurement of reporting results (cases: reporting all
strokes irrespective of management outcome, study population:
reporting of all hospitalized SARS-CoV-2 patients). We demonstrated
the outcomes in Supplemental Table 1 (page 9) for each center
included in the meta-analyses. The summary of the outcomes was
presented as a percentage of the centres with no information, low,
medium, or high risk of bias under each category.
Heterogeneity among study levels was assessed with the Cochran
Q test (x2 test for heterogeneity). The proportion of total heterogene-
ity to total variability was quantified by I2 and its 95% confidence
interval (CI). The Q-test with p<0.1 or an I2 statistic greater than 50%
was considered statistically significant [44]. We visualizedsubsequent stroke risk (95% CIs) following SARS-CoV-2 infection by
forest plots. To better present the possible risk difference among
centres, we conducted meta-analyses under five different levels: 1)
Regions (states/districts) in each country, 2) Countries grouped by
continent, 3) Data limited to countries with higher health expendi-
tures, 4) Removal of the centres with the highest and lowest risk esti-
mation, 5) Type of data for study population (individual versus
summary level). Details on countries’ health expenditures according
to the WHO report [45], are available in Supplemental Table 2 (page
15). One center in the United States (New York-2) provided the
patient-level data by automated data extraction and natural language
processing from their electronic health records system. The investiga-
tor in that center was not able to perform a manual chart review of
the stroke patients to further validate the findings. We did not
include the centres that could not provide an accurate total number
of strokes (numerator) or study population (denominator) for risk
calculations. To minimize the impact of the low denominator [46],
we did not include the regions with fewer than 20 hospitalized
patients in the meta-analyses. We used random-effects models with
double arcsine transformations and DerSimonian-Laird estimator in
all meta-analyses. The meta-analyses were performed using the R
version 3.5.0 andmetafor [47] package.
3. Role of the funding source
There was no funding source for this study.
4. Results
We received data from 26,175 hospitalized SARS-CoV-2 patients
from 99 tertiary centres in 65 regions in 11 countries
(Supplemental Fig. 1, page 19). A total of 8376 patients were excluded
from this study (available study population but unverified stroke
cases: 6287; partial reports of stroke patients: 2022; study popula-
tion less than 20 individuals: 50; no data available on study popula-
tion: 17; Supplemental Table 3, page 17). The study included 17,799
SARS-CoV-2 infected patients—156 patients with stroke. Table 1
presents the comorbidities and laboratory results among the patients
with stroke and a subset of non-stroke patients with available
detailed data. Among the 156 stroke patients, 123 (79%) presented
with acute ischaemic stroke, 27 (17%) with intracerebral/subarach-
noid hemorrhage, and 6 (4%) with cerebral venous or sinus thrombo-
sis (Table 2). We observed mean age of 68.6 (13.9) years among
patients with ischaemic stroke, 62.5 (15.3) years in patients with
intracranial hemorrhage, and 50.3 (12.9) in patients with cerebral
venous thrombosis. Overall, 43 (27.6%) of the stroke patients pre-
sented to the medical centres with stroke-related symptoms as the
chief complaint, without the prior diagnosis of SAR-CoV-2 infection.
Patients with an acute ischaemic stroke had a median NIHSS of 9.5
[6.019.0] on admission. Among the available 80 (65%) MR imaging
for assessment, the ischaemic strokes could be considered as lacunar
in 6 (7.5%), embolic/large vessel athero-thromboembolism in 58
(72.5%), or other phenotypes (borderzone or equivocal; 16, 20.0%).
Patients with intracerebral/subarachnoid hemorrhage presented
with an NIHSS of 13 [8.017.0] and intracerebral hemorrhage (ICH)
score of 3.0 [2.04.0]. Among the latter, 25 (93%) had an intracerebral
hemorrhage, and 2 (7%) had a subarachnoid hemorrhage. Among the
6 patients with cerebral venous thrombosis, 2 (33%) patients had epi-
sodes of seizures prior to admission. Supplemental Figures 24 (page
21) presents the clinical imaging of selected patients.
The details of the risk of bias assessment are available in
Supplemental Table 1A, B (page 9). To summarize, 25 out of 99 (25%)
centres (19 strokes in 8376 study population) were excluded from
meta-analyses. One center in the United States (New York-2) pro-
vided stroke data by automated data extraction and natural language
processing without chart review validation. Therefore, all the meta-
Table 1
The baseline characteristics, comorbidities, and laboratory findings among patients with and without stroke.
Parameter Stroke (N = 156) Without Stroke (N = 6200)* p-Value
Age; Mean (SD); Years 66 (15) 58 (14) <0.0001
Age; Median [IQR]; Years 67 [5778] 63 [5563] <0.0001
<40 6 (5.4) 412 (14) 0.003
4064 42 (37.8) 2205 (74.7)
6574 25 (22.5) 192 (6.5)
75 38 (34.2) 144 (4.9)
Sex; Female; N (%) 47 (42) 2512 (41) 0.76
Mechanical Ventilation; N (%) 31 (37) 428 (14) <0.0001
Hypertension; N (%) 61 (65) 1912 (42) <0.0001
Diabetes Mellitus; N (%) 32 (34) 1312 (28) 0.23
Ischaemic Heart Disease; N (%) 28 (30) 560 (12) <0.0001
Atrial Fibrillation; N (%) 9 (10) 178 (7) 0.25
Carotid Stenosis; N (%) 8 (9) 349 (13) 0.28
Smoking; N (%) 15 (16) 385 (17) 0.59
Prior Stroke or Transient Ischemic Attack; N (%) 14 (15) 189 (7) 0.003
White Blood Cell Count x109/L; Mean (SD) 10.3 (8.4) 10.1 (18.5) 0.93
White Blood Cell Count x109/L; Median [IQR] 9.0 [6.312.2] 6.9 [5.19.9] 0.01
<4 £ 109/L 2 (2.4) 64 (11.6) 0.003
410 £ 109/L 49 (57.6) 348 (63.2)
1020 £ 109/L 30 (35.3) 113 (20.5)
20 £ 109/L 4 (4.7) 26 (4.7)
Neutrophil Count x109/L; Mean (SD) 9.6 (12.9) 8.3 (15.4) 0.48
Neutrophil Count x109/L; Median [IQR] 6.6 [4.59.4] 5 [3.48.2] 0.08
<4 £ 109/L 10 (13.3) 142 (33.2) 0.01
410 £ 109/L 49 (65.3) 217 (50.7)
1020 £ 109/L 13 (17.3) 56 (13.1)
20 £ 109/L 3 (4) 13 (3)
Lymphocyte Count x109/L; Mean (SD) 1.8 (1.6) 1.1 (3.8) 0.14
Lymphocyte x109/L; Median [IQR] 1.4 [1.22] 0.9 [0.71.4] <0.001
<1 £ 109/L 13 (15.5) 2360 (85.9) <0.0001
12 £ 109/L 49 (58.3) 243 (8.8)
23 £ 109/L 17 (20.2) 92 (3.3)
34 £ 109/L 3 (3.6) 31 (1.1)
4 £ 109/L 2 (2.4) 22 (0.8)
Neutrophil/Lymphocyte Ratio; Mean (SD) 7.39 (9.74) 6.34 (6.22) 0.21
Neutrophil/Lymphocyte Ratio; Median [IQR] 4.44 [37.32] 4.34 [2.57.6] 0.96
Platelet Count x109/L; Mean (SD) 212.7 (105.7) 200.5 (47.8) 0.02
Platelet Count x109/L; Median [IQR] 179.5 [145283] 195 [152253] 0.73
<350 £ 109/L 71 (88.8) 2693 (97.9) <0.0001
350500 £ 109/L 9 (11.3) 57 (2.1)
Alanine Transaminase (ALT) U/L; Mean (SD) 50.8 (86.4) 38.3 (48.2) 0.07
Alanine Transaminase (ALT) U/L; Median [IQR] 31 [21.744.5] 29 [1844] 0.53
Aspartate Transaminase (AST) U/L; Mean (SD) 59.6 (98.7) 44.1 (41.8) 0.24
Aspartate Transaminase (AST) U/L; Median [IQR] 35 [2553] 35 [2550] 0.93
Blood Urea Nitrogen (BUN) mg/dl; Mean (SD) 25.8 (21.9) 22.3 (24.7) 0.25
Blood Urea Nitrogen (BUN) mg/dl; Median [IQR] 19 [1329.6] 15.8 [9.724] 0.12
Creatinine mg/dl; Mean (SD) 1.5 (1.3) 1.3 (1.0) 0.21
Creatinine mg/dl; Median [IQR] 1.1 (0.91.5) 1.1 (0.91.4) 0.94
C-Reactive Protein (CRP) mg/L; Mean (SD) 60.5 (65.7)y 84 (74.9) <0.001
C-Reactive Protein (CRP) mg/L; Median [IQR] 31 [1285.5]y 65 [26.4119.75] <0.001
* Data regarding 6200 patients were received in details. Other centers provided summary data that could not be
used for comparison.
y Data with qualitative scale were excluded from the analyses.
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this center (Forest Plots 14 in Supplemental Figs. 58, page 25).
When considering all the available data after quality and risk of
bias assessment, the risk of subsequent stroke in the infected patients
with SARS-Cov-2 is 156/17,799 (0.9%, non-weighted simple pooled
analysis). A meta-analysis of data from 43 regions (Fig. 1) suggests an
overall stroke risk of 0.5% [95% CI, 0.3%0.7%]. When grouping the
centres by continent, the risk of subsequent stroke is 1.2% [95% CI,
0.9%1.6%] in North America, 0.5% [95% CI, 0.1%1.1%] in Europe,
0.3% [95% CI, 0.0%0.9%] in Asia, and 0.0% in Oceania (Fig. 2). To con-
trol for possible unseen heterogeneity among countries with higher
and lower health expenditures in terms of the diagnosis or quality of
care, we repeated the analysis by including only 27 regions with
higher health expenditures (Fig. 3). The overall stroke risk among
these 27 regions is 0.7% [95% CI, 0.2%1.6%]. The repeated meta-analysis after removing the centres with the highest and lowest cal-
culated risk suggests a comparable stroke risk of 0.6% [95% CI,
0.5%0.8%] (Supplemental Figure 8, page 29). Grouping the regions
based on the received data type resulted in the risk of 0.6%
[0.0%1.7%] for regions that provided the individual level data for all
the study population, and 0.5% [0.2%0.7%] for regions that either
presented summary level data or could provide individual level data
for only a subset of the study population (Supplemental Figure 9,
page 30). All analyses were conducted under low heterogeneity
among study levels (I2<50%). When comparing patients with and
without a subsequent stroke, there were significant differences in
age, needs for mechanical ventilation, hypertension, ischaemic heart
disease, prior stroke or transient ischaemic attack, platelets counts,
white blood cells, neutrophils and lymphocytes counts, and C-reac-
tive protein (CRP) between the two groups (all p<0.01; Table 1).
Table 2
Baseline characteristics and clinical details of patients with cerebrovascular events.
Stroke
Parameter
Acute Ischaemic Stroke
N = 123 (79%)
Intracranial Haemorrhage
N = 27 (17%)
Cerebral Venous Thrombosis
N = 6 (4%)
Age; Mean (SD); Years 68.6 (13.9) 62.5 (15.3) 50.3 (12.9)
Age; Median [IQR]; Years 71.0 [58.278.0] 62.0 [52.571.5] 54.0 [39.058.0]
Sex; Female; N (%) 56 (46) 8 (30) 4 (67)
Interval Between SARSCoV-2 Onset to Stroke;
Median [IQR]; Days
3 [07] 1 [05] 4.5 [214]
Stroke-Related Symptoms as the Chief Complaint; N (%) 31 (25) 11 (41) 1 (17)
Large Vessel Occlusion; N (%) 27/72 (37.5)  
Intravenous Thrombolysis; N (%) 7/80 (8.8)  
National Institutes of Health Stroke Scale (NIHSS) Score; Median [IQR] 9.5 [6.019.0] 13 [8.017.0] 
Intracerebral Haemorrhage (ICH) Score; Median [IQR]  3.0 [2.04.0] 
Imaging Pattern; N (%) Embolic / large vessel
athero-thromboem-
bolism: 58/80 (72.5) *
Intracerebral Haemorrhage: 25 (92.6) 
Lacunar: 6/80 (7.5) * Subarachnoid Haemorrhage: 2 (7.4) 
Other: 16/80 (20.0)*,y  
* The magnetic resonance imaging (MRI) details of 80 patients were available.
y Borderzone stroke or equivocal lesions.
Fig. 1. Forest Plot; risk of subsequent stroke in patients infected with SARS-CoV-2, presented for regions in each country.
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Fig. 2. Forest Plot; risk of subsequent stroke in patients infected with SARS-CoV-2, Presented for countries grouped by continents.
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Nagelkerke R Square: 0.152) suggested that mechanical ventilation
(OR: 1.9, 95% CI:1.13.5, p = 0.028), and the presence of ischaemic
heart disease (OR: 2.5, 95% CI: 1.44.7, p = 0.006) are independent
predictors of stroke. When we repeated the analysis after excluding
the need for ventilation (given the limited number of patients on a
ventilator), ischaemic heart disease remained the only independent
predictor of stroke.
5. Discussion
The results of this multi-national study on hospitalized patients
with SARS-CoV-2 infection indicated an overall stroke risk of 0.5%
(pooled risk: 0.9%). This frequency was obtained after a careful qual-
ity and heterogeneity assessment of the data. The results of regres-
sion models suggest that the need for mechanical ventilation and a
history of ischaemic heart disease are the independent predictors of
stroke among SARS-CoV-2 hospitalized patients.
Since the onset of the pandemic, a large population across the
globe have been diagnosed with SARS-CoV-2 and several had associ-
ated neurological symptoms [11,4850]. Recently, there has beenincreasing attention on the vascular complications of SARS-CoV-2,
and different pathophysiologic mechanisms have been proposed to
underpin such events; among them, one can mention vasoconstric-
tion and increased blood pressure through an imbalance of Angioten-
sin-Converting Enzyme (ACE) and ACE-2 activation, immune-
mediated mechanisms and overexpression of the cytokines, vasculi-
tis, and neurological consequences secondary to hypoxemia or hypo-
tension [3,7,8,10,51]. Increased proinflammatory biomarkers [52,53],
and COVID-19-associated coagulopathy, characterized by increased
fibrinogen/fibrinogen degradation products and D-dimer levels
[1214] were also reported in patients with SARS-CoV-2 infection.
Further reports supported higher thrombotic complications such as
ischaemic stroke, systemic arterial embolism, and venous thrombo-
embolism in SARS-CoV-2 infected patients [54,55].
To date, several series of strokes in patients with SARS-CoV-2
diagnoses have been reported [3,4,56]. However, to our knowledge,
no prior study has determined the rate of these complications at a
multinational level. A temporal relationship and increased risk of
stroke have been reported in association with different respiratory
viral infections [1523]. A population-based study in the United
Kingdom (UK) on 2874 patients demonstrated an increased number
Fig. 3. Forest Plot; risk of subsequent stroke in patients infected with SARS-CoV-2, Data limited to countries with higher health expenditure.
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(haemorrhagic stroke) after seasonal influenza peak [15]. Another
population study from the UK on 22,400 individuals reported an
increased risk of vascular events following lower respiratory or uri-
nary tract infections, with an age-adjusted incidence ratio of 3.2
within the first three days, which decreased to 1.33 within three
months post-infection [16]. In California, a study of about 37,000 hos-
pitalized ischaemic stroke patients suggested a significant risk of
stroke in patients with prior influenza-like illnesses, with odds ratios
(OR) of 2.9 in 15 days, decreasing to 1.7 within 365 days post-infec-
tion [17]. Based on this study, stroke triggered by influenza-like infec-
tions are more likely to occur in patients who are younger than
45 years old (OR: 9.28, in comparison to OR: 2.71 in 4565 years old,
and OR: 2.65 in patients older than 65). A recent meta-analysis
showed that influenza vaccination might be associated with a lower
risk of ischaemic stroke events [57]. Despite this, the overall risk of
subsequent stroke seems to be less than 1%. In another study of over
102,500 patients with a diagnosis of influenza, stroke or TIA inci-
dence rates were reported to be 0.052, 0.035, 0.029 at 1, 3, and 6
months after influenza [19]. Likewise, the United States National
Readmissions Database reports on over 46,000 patients hospitalized
for influenza indicated that strokes are infrequent (0.3%) causes of
30-day readmission [18].
Strokes were also reported among patients infected with b-coro-
naviruses such as severe acute respiratory syndrome (SARS) or Mid-
dle East respiratory syndrome coronavirus (MERS-CoV) [2023]. Five(2%) patients infected with SARS in Singapore developed large artery
cerebral ischemia, among them three had no known stroke risk factor
[20]. Acute myocardial infarction and disseminated intravascular
coagulation (three patients), and generalized hypotension (four
patients) preceded the ischaemic stroke event. Bilateral anterior cere-
bral artery stroke (a diabetic and hypertensive 57-year old man) [21],
frontal lobes intracerebral hemorrhage (a diabetic 34-year old
woman) [22], and frontal hematoma and subarachnoid hemorrhage
extending to ventricles that resulted in subfalcine herniation (a dia-
betic 42-year old woman, with history of nephrectomy) [23] were
reported in association with MERS-CoV infection. To the best of our
knowledge, the literature is limited to small case series, and no popu-
lation-based rate assumption has been provided for these viral infec-
tions.
Although an increasing number of reports on neurological symp-
toms have been published since the onset of the SARS-CoV-2 out-
break, confirmed cases of cerebrovascular events in association with
SARS-CoV-2 are limited. Zhang et al. described three Chinese patients
who experienced multiple cerebral infarctions [4]. All of these
patients were in critical conditions, significant coagulopathy, and
antiphospholipid antibodies (positive anticardiolipin IgA, antib2-
glycoprotein I IgA and IgG). In another case series from China, 13 out
of 221 patients (6%) had strokes: large vessel stroke in five, small ves-
sel stroke in three, cardioembolic stroke in three, and two patients
were complicated with cerebral venous thrombosis and cerebral
hemorrhage [3]. In a series of six patients from the UK, all patients
S. Shahjouei et al. / EBioMedicine 59 (2020) 102939 9had large vessel occlusion (three in multiple vascular territories) with
elevated D-dimer levels, among whom the stroke was the primary
presentation of SARS-CoV-2 in one patient. Five patients had positive
lupus anticoagulants, but only one had medium titter antiphospholi-
pid IgM and IgG antibodies. All patients in this series were over
50 years old and had moderate to severe SARS-CoV-2 infection [5]. In
a case series from New York City, five patients, younger than 50 years
old with a positive test for SARS-CoV-2, developed large-vessel stroke
[6]. Three of these patients had prior comorbidities—39 years old
with hypertension and dyslipidaemia, 44 years old with diabetes
mellitus, and 49 years old with diabetes and prior stroke. The authors
stated that based on the routine admission rate of their center over
the past year, the rate of young adults with large vessel stroke might
be higher. Unfortunately, the authors provided no information
regarding the total hospitalized patients with SARS-CoV-2 for further
risk calculation.
It is worth mentioning that most of the reported SARS-CoV-2
infected patients with stroke had critical conditions. In this study, the
patients with stroke were more likely on a ventilator (36.5% versus
14.0%) and had ischaemic heart disease (29.8% versus 12.1%). Patients
who receive invasive mechanical ventilation are more likely to have
elevated inflammatory markers, comorbidities, and the need for
vasopressor and ionotropic agents [58]. Inflammation, coagulation
disorder, and infection in critically ill patients may also favor a stroke
[59]. About 0.5% of patients hospitalized with sepsis experience
stroke within one year [24]. Sepsis can put patients at higher risks of
ischaemic (OR>28) or haemorrhagic strokes (OR>12) through the
first two weeks; the risk would remain high even for up to one year
[60]. A variety of mechanisms can induce coagulopathy in sepsis
[25,26]. In addition, about 6% of patients with severe sepsis experi-
ence new-onset of atrial fibrillation, which can put them at a greater
risk of in-hospital stroke (2.6%) and in-hospital mortality (56%) [27].
New-onset atrial fibrillation is not limited to sepsis and can occur up
to 8% of the ICU admissions, leading to an increased length of stay,
mortality, and poor outcomes [61].
The authors communicated with different centres in several coun-
tries to increase the representativeness of this study. However, due to
the sensitive nature of the SARS-CoV-2 outbreak, the high load of
patients, and lack of electronic health records and resources to
extract data, or lack of priority, the recruited data were limited to 99
centres from 11 countries. We had to exclude 25% of patients from
the analyses due to the unavailability of validated data. The above
missingness may have introduced selection-bias and affected the
generalizability of the results or weaken the conclusion that can be
drawn about the phenotype and mechanisms of stroke in SARS-CoV-
2. Nevertheless, we did not observe any significant heterogeneity in
our subgroup meta- and sensitivity analyses.
In our study, the overall estimated risk in the meta-analysis of all
centres was 0.5%. This risk would be comparable to the reported inci-
dence of stroke following influenza [18,19]. When we conducted the
meta-analyses by continent, we observed a subsequent stroke risk of
0.71.2% in North America, 0.5% in Europe, and 0.3% in Asia. This dif-
ference might be due to many factors including policy variation
among different healthcare systems for the hospitalization of SARS-
CoV-2 infected patients; some centres had relaxed criteria for admis-
sion of positively tested patients, while the others were over-
whelmed and adopted strict criteria to hospitalize patients. The other
factor might be the confirmation of the SARS-CoV-2 infection. Due to
the low sensitivity of PCR [62,63], the testing interval, and also avail-
ability and capacity of testing sites, some centres considered chest CT
scan in addition to the presence of symptoms indicative of SARS-
CoV-2 infection. Nevertheless, in our study, the stroke risk was esti-
mated as 0.7% among countries with higher health expenditures
which only used PCR for infection confirmation. This rate was similar
to our overall risk estimates; pooled risk estimates of 0.9% and
weighted risk of 0.5%. Although our study includes several countriesand communities and has high generalization power for the calcu-
lated risk, we realize that the risk factors associated with stroke could
have been different if the study was done at the community level;
secondary to a different profile of vascular risk factors, genetic predis-
position, and sociodemographic factors.
We did not have a central adjudication in this study. In addition, we
realize that the clinical severity could be assessed through other param-
eters that could not be collected considering the high number of partici-
pating centres, the partial availability of data, and the narrow study time
window. Various centres may have had a different treatment protocol
based on local experience that could not be fully taken into consider-
ation. Despite these possible limitations, the availability of richer clinical
data or care procedures would not suggest results very different from
those presented. At the same time, the pooled and meta-analyses for
risk calculation did not require detailed clinical data.
We made attempts to capture data from all the regional hospitals
for SARS-CoV-2 infection and stroke-related readmissions; however,
there is the possibility of not capturing stroke or other cerebrovascu-
lar events in the convalescence stage. Despite our attempt to capture
the whole referral region, patients’ mobility among nearby regions to
obtain the best medical services might have introduced bias in the
risk estimation.We realize that the SARS-CoV-2 epidemic has affected
the care-seeking behaviours of patients with neurological symptoms
and has exhausted care deliveries in several health systems. We also
recognize that decreased quality of care, long wait-time for conduct-
ing neuroimaging, and rapid deterioration of SARS-CoV-2 infected
patients or being on a ventilator may have led to some patients with
mild stroke-like symptoms not receiving further relevant investiga-
tion and diagnosis. To partially alleviate the effect of some of the limi-
tations, we provided different levels of meta-analysis in this study.
The results of this multi-national study on hospitalized patients
with SARS-CoV-2 infection indicated an overall stroke risk of 0.5%
(pooled risk: 0.9%). This number will be lower if all patients with
SARS-CoV-2 diagnosis are considered rather than hospitalized
patients. The need for mechanical ventilation and ischaemic heart
disease are the independent predictors of stroke among SARS-CoV-2
patients.
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